Genscript Biotech (HK:1548) has released an update.
Genscript Biotech Corporation has announced the issuance of 68,054 restricted shares to consultants under its RSA Scheme 2021, aiming to incentivize and align their interests with the company’s long-term growth. Granted on July 8, 2024, these shares represent a minor 0.0032% of the company’s issued share capital and will vest between August 2025 and August 2027, with no performance targets or clawback mechanism attached.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
